Adherex Technologies Inc.

Adherex Technologies Inc.

April 05, 2006 08:15 ET

Adherex Executes Clinical Trial Agreement for ADH-1 With the National Cancer Institute: Agreement implements collaboration approved in 2005

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(CCNMatthews - April 5, 2006) - Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Company and the U.S. National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis have executed a Clinical Trial Agreement (CTA) for the evaluation of Adherex's lead biotechnology compound ADH-1. The agreement provides for the NCI to sponsor non-clinical studies and clinical trials of ADH-1 in a variety of administration schedules and tumor types, both as a single agent and in combination with other anti-cancer agents.

"Through this agreement, we can move forward with our collaboration with the NCI and gain access to its broad network of scientists conducting NCI-sponsored clinical trials," said William P. Peters, M.D., Ph.D., Chairman and CEO of Adherex. "Through the CTA, the NCI studies will complement our own single-agent and combination studies of ADH-1 and further our understanding of how best to use this drug."

The NCI, which is part of the National Institutes of Health (NIH), plans to conduct studies to further evaluate ADH-1's anti-cancer and vascular targeting effects, both as a single agent and in combination with other agents. The exact design of these studies will be determined jointly by the NCI and Adherex.

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including ADH-1 (Exherin™), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at

This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the development plans of the Company and the expected timing and results of such development. We can provide no assurance that such development will proceed as currently anticipated or that the expected timing or results of such development will be realized. We are subject to various risks, including our reliance on collaborative partners, the uncertainties of clinical trials, drug development and regulatory review, other risks inherent in the biopharmaceutical industry, the early stage of our product candidates, our need for additional capital to fund our operations, and our history of losses. For a more detailed discussion of related risk factors, please refer to our public filings available at and

Contact Information

  • Adherex Technologies Inc.
    Melissa Matson
    Director, Corporate Communications
    (919) 484-8484